ClinicalTrials.gg
Active, not recruitingNCT06941558UK ADAPTISUpdated Apr 23, 2026

The UK ADAPTIS Study

An interventional study of INFINITY™ with ADAPTIS™ and EVERLAST™ in Total Ankle Replacement and Total Ankle Arthroplasty, sponsored by Northumbria Healthcare NHS Foundation Trust. Active, not recruiting at 1 site in United Kingdom. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Northumbria Healthcare NHS Foundation Trust · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Apr 2024, registered Mar 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
21 Years and older
Sex
All
01

Study summary

An ankle replacement procedure consists of replacing the worn-out joint surfaces of the ankle with metal and plastic components that are shaped to allow continued movement of the ankle. There are several different types of ankle replacement available. Infinity ankle implants are already routinely used in NHS hospitals. The INFINITY™ with ADAPTIS™ and EVERLAST™ ankle replacement system is a development of the Infinity ankle implant, designed to attach to the bone better and to wear out more slowly.

The purpose of the UK ADAPTIS™ Study is to assess the performance and function of the newly introduced INFINITY™ with ADAPTIS™ and EVERLAST™ technology Total Ankle System for total ankle replacement (TAR) or arthroplasty (TAA) and EVERLAST™ Poly Insert that modernises and streamlines Stryker's TAA/TAR portfolio.

UK ADAPTIS is a prospective multi-centre cohort series of INFINITY™ with ADAPTIS™ and EVERLAST™ Technology with Poly Insert for patients requiring primary total ankle replacement (TAR) i.e. Total Ankle Arthroplasty (TAA).

Patients meeting the criteria for the study will be asked to enrol by providing written informed consent.

The patients will be monitored clinically by post-operative follow-up examinations and Patient reported outcome measures (PROMs) (Manchester Oxford Foot \& Ankle Questionnaire (MOXFQ), Ankle Osteoarthritis Scale (AOS), EQ5D-5L).

Intended use:

It is intended to give a patient limited mobility by reducing pain, restoring alignment, and replacing flexion and extension movement in the ankle joint.

Indications for use:

  • Patients with ankle joints damaged by severe rheumatoid, post-traumatic, or degenerative arthritis.
  • Patients with a failed previous ankle surgery.
02

Conditions studied

  • Total Ankle Replacement
  • Total Ankle Arthroplasty
03

In context

Lead sponsor

Northumbria Healthcare NHS Foundation Trust is the lead sponsor of 16 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or non-pregnant female over the age of 21 years with a diagnosis of end stage ankle arthritis and requiring primary TAA/TAR and is suitable for the use of the ADAPTIS TAA/TAR
  2. Patients who are physically and mentally willing and able to comply with the post-operative follow-ups and an appropriate rehabilitation schedule.
  3. Patient can understand and provide written consent.

Exclusion criteria

Exclusion Criteria:

  1. Patients with previous ankle arthrodesis or Patients who require revision of previously implanted TAA/TAR.
  2. Any patients presenting with conditions prior to implantation, that would contraindicate implantation of a TAA/TAR
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Other
    INFINITY™ with ADAPTIS™ and EVERLAST™

    INFINITY™ with ADAPTIS™ and EVERLAST™ technology with Poly Insert for patients requiring primary TAA/TAR.

    Device: INFINITY™ with ADAPTIS™ and EVERLAST™

Interventions

  • DeviceINFINITY™ with ADAPTIS™ and EVERLAST™

    The INFINITY™ with ADAPTIS™ and EVERLAST™ ankle replacement system is a development of the Infinity ankle implant, designed to attach to the bone better and to wear out more slowly.

06

What researchers measure

Primary outcomes

  1. Functional Status

    Functional status using MOXFQ (Manchester-Oxford Foot Questionnaire). The MOXFQ is scored on a 0-100 scale, where higher scores indicate more severe problems.

    Time frame: 2 years

  2. Device Survivorship

    Device survivorship, assessed by tracking revision rates

    Time frame: 2 years

  3. Device Survivorship

    Device survivorship, assessed by tracking re-operations

    Time frame: 2 years

  4. Device Survivorship

    Device survivorship, assessed by adverse events

    Time frame: 2 years

Secondary outcomes

  1. Pain and Disability

    Pain and disability assessed using AOS (Ankle Osteoarthritis Scale) questionnaire. A higher score on the AOS reflects greater pain, functional limitations, and a generally poorer overall ankle-related health status.

    Time frame: Up to 5 years post-op

  2. Pain and Disability

    Pain and disability assessed using MOXFQ (Manchester-Oxford Foot Questionnaire). The MOXFQ is scored on a 0-100 scale, where higher scores indicate more severe problems.

    Time frame: Up to 5 years post-op

  3. Pain and Disability

    Pain and disability assessed using a specific health-related quality of life questionnaire (EQ5D-5L)

    Time frame: Up to 5 years post-op

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — It is anticipated that a publication of the anonymous study results will be compiled and submitted to a peer-reviewed journal. The CI of the study will have the responsibility of being primary author of such publications. The study will be registered in the ISRCTN Trial Register and/or in clinicaltrials.gov by the CI.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Sep 2027, 41 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2025
First posted
Apr 23, 2025
StartActual
Apr 23, 2024
Primary completionEst.
Sep 2027
CompletionEst.
Apr 2031
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06941558
Lead sponsor
Northumbria Healthcare NHS Foundation Trust
Collaborators
South Tees Hospitals NHS Foundation Trust
Responsible party
Sponsor
First posted
Apr 23, 2025
Start date
Apr 23, 2024
Primary completion
Sep 2027 (estimated)
Completion
Apr 2031 (estimated)
Last update
Apr 23, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion